Form 4: Beam Therapeutics Director Receives Stock Option Grant

Director Graham K. Cooper was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Summary

• Director Graham K. Cooper received a grant of 19,676 stock options on June 3, 2026.
• The options have an exercise price of $29.55 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs on the earlier of the first anniversary of the grant or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $29.55 exercise price.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant or the next annual meeting, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 3, 2027, or the 2027 annual meeting of stockholders.

Key Dates

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Stock Options, Biotech, Equity Compensation